| Increased expression of the tumor suppressor PLZF in malignant melanomas is associated with long-term patient survival. | skin, |
| Role of PLZF as a tumor suppressor in prostate cancer | prostate, |
| Tumor suppressor PLZF regulated by lncRNA ANRIL suppresses proliferation and epithelial mesenchymal transformation of gastric cancer cells | gastric, |
| Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer | prostate, |
| Study demonstrates that miR-4319 is expressed at a low level in colorectal cancer (CRC) tissues, which predicts the poor clinical outcome of CRC. MiR-4319 regulates the proliferation, cell cycle, invasion and migration of CRC cells. Mechanically, miR-4319 is found to be transcriptionally regulated by PLZF, and acts as a tumour suppressor in CRC by targeting ABTB1. | colorectal, |
| Crosstalk Between Prostate Cancer Cells and Tumor-Associated Fibroblasts Enhances the Malignancy by Inhibiting the Tumor Suppressor PLZF | prostate, |
| Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) protein, its homologue FAZF, and the t(11;17)-generated PLZF-retinoic acid receptor alpha oncoprotein. | leukemia, |
| Promyelocytic leukemia zinc finger-retinoic acid receptor alpha (PLZF-RARalpha), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes. | leukemia, |
| Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. | None |
| The 2 PLZF mutants are oncogenic, because they function as dominant negatives of wild-type PLZF, enhancing Myc phosphorylation and increasing Myc transcriptional and oncogenic activity. | None |
| The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability. | None |
| PLZF-RARalpha as an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes | None |
| Overexpression, purification, characterization, and crystallization of the BTB/POZ domain from the PLZF oncoprotein. | None |